Research
Psychedelic Research Opportunities for Mental Health in San Diego
Helping develop the next generation of advanced treatments through research is part of our mission at Kadima Neuropsychiatry
Research
Helping develop the next generation of advanced treatments through research is part of our mission at Kadima
Our Research
Kadima Neuropsychiatry is at the forefront of advancing mental health care through clinical research. We conduct FDA regulated trials exploring next generation treatments for mood disorders such as depression, anxiety, and PTSD.
Our current and upcoming studies explore a wide range of investigational treatments, including psychedelics (such as psilocybin, psilocin, LSD, DMT, and 5-MeO-DMT), novel forms of ketamine, breakthrough medications with new mechanisms of action, advanced medical devices and virtual reality therapies.
We are actively enrolling participants for these studies.
Psychedelic Research Substances We Explore:
LSD
Lysergic acid diethylamide
Psilocybin
“magic mushrooms”
DMT & 5-MeO-DMT
5-methoxy-N,N-dimethyltryptamine
Active Research
Study of a pharmaceutical formulation of Psilocin for Depression
Investigational Treatment:
Study of a pharmaceutical formulation of LSD for Generalized Anxiety Disorder
Investigational Treatment:
Study of a formulation of psychedelic for Treatment Resistant Depression
Investigational Treatment:
Study of a psychedelic for Adjustment Disorder in Cancer patients
Investigational Treatment:
Clinical Trial Summary: A Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study Evaluating the Safety and Efficacy of RE104 for Injection in the Treatment of Adjustment Disorder in Patients With Cancer and Other Medical Illnesses
Study of Psilocybin for Depression
Investigational Treatment: A Phase III, multicentre, randomised, double-blind, placebo-controlled study to investigate the efficacy, safety, and tolerability of COMP360 (Psilocybin) in participants with treatment-resistant depression. Learn more about the investigational treatment.
Study of Deep TMS for Alcohol Use Disorder
Investigational Treatment:
A Prospective, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for reducing heavy alcohol drinking in individuals with Alcohol Use Disorder (AUD).
Quick & Simple Application Process
Three straightforward steps to determine your eligibility for our trials.
Eligibility Application
Complete our quick eligibility application to see which trials may be a fit for you.
Screening Call
Speak with our study recruiter to confirm your eligibility and answer any questions.
Enrollment
If eligible and consenting, you will be enrolled and begin the study with our team.
Upcoming Clinical Trials
Our Study Sponsors and Partners
Kernel Predict Study
Using Kernel Flow brain imaging to predict response to depression treatment.
Beckley Psytech, BPL-003
Phase 2b of BPL-003 (5-MeO-DMT) in participants with Depression. Read More.
Mind Medicine, MMED 120
Phase 2b of MMED 120 (LSD-tartrate) in participants with Generalized Anxiety Disorder. Read More
Compass Pathways, COMP001
The safety and efficacy of psilocybin in participants with Treatment Resistant Depression. Read More
Compass Pathways, COMP003
The safety and efficacy Of psilocybin as an adjunctive therapy in participants with Treatment Resistant Depression. Read More
Tripp PsyAssist
Effects of a Virtual Reality PsyAssist Calm Experience Program on Pre-treatment Anxiety Prior to Ketamine Dosing
Brainsway
Cognitive Behavioral Therapy (CBT) in adjunct with Deep Transcranial Magnetic Stimulation (dTMS) for Major Depressive Disorder (MDD)
Relivion DP Study
Study evaluating a Brain Neuromodulation system for the Treatment of Major Depressive Disorder (MDD).
Perception Neuroscience, Inc, PCN-101
The safety and efficacy of PCN-101 (R-Ketamine) in participants with Treatment Resistant Depression. Read More